Korean J Gastroenterol.
2020 Apr;75(4):228-230. 10.4166/kjg.2020.75.4.228.
Could Preoperative Chemoradiotherapy Lead to the Survival Benefit of Patients with Resectable Pancreatic Cancer?
- Affiliations
-
- 1Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
- KMID: 2504242
- DOI: http://doi.org/10.4166/kjg.2020.75.4.228
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Role of Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer
- Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
- Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
- Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
- Preoperative Chemotherapy in Advanced Stomach Cancer (Cons)
